VETRIS CV included all patients with diabetes and ACD and found that SGLT2 only reduced the hospitalization rate of HF and had no obvious benefit for cardiovascular events, such as MACEs, CV death, and MI (22). The gene discussed is SLC5A2; the disease is diabetes mellitus.